- Home
- HQL vs FDMT Comparison
HQL vs FDMT Comparison
Compare HQL & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HQL | FDMT |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.5M | 513.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HQL | FDMT |
|---|---|---|
| Price | $16.45 | $8.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.40 |
| AVG Volume (30 Days) | 114.0K | ★ 620.3K |
| Earning Date | 01-01-0001 | 03-18-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | N/A | ★ $37,000.00 |
| Revenue This Year | N/A | $21,227.03 |
| Revenue Next Year | N/A | $161.87 |
| P/E Ratio | $20.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.55 | $2.24 |
| 52 Week High | $17.80 | $12.34 |
Technical Indicators
Market Signals| Indicator | HQL | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 45.04 |
| Support Level | $15.66 | $8.15 |
| Resistance Level | $17.51 | $8.80 |
| Average True Range (ATR) | 0.31 | 0.51 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 58.73 | 21.61 |
Price Performance
Historical ComparisonAbout HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.